Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate^®) in hemophilia A

References

• StonebrakerJSBolton-MaggsPHSoucieJMWalkerIBrookerMA study of variations in the reported haemophilia A prevalence around the worldHaemophilia2010161203219845775
   PubMed Web of Science ®Google Scholar
• MannucciPMTuddenhamEGThe hemophilias – from royal genes to gene therapyN Engl J Med2001344231773177911396445
   PubMed Web of Science ®Google Scholar
• WhiteGC2ndRosendaalFAledortLMLusherJMRothschildCIngerslevJDefinitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and HaemostasisThromb Haemost200185356011307831
   PubMed Web of Science ®Google Scholar
• LeeCAFront matterTextbook of HemophiliaNew York, NYJohn Wiley and Sons, Ltd2014ixxi
   Google Scholar
• ReitterSWaldhoerTVutucCLechnerKPabingerISurvival in a cohort of patients with haemophilia at the haemophilia care center in Vienna, Austria, from 1983 to 2006Haemophilia200915488889319473415
   PubMed Web of Science ®Google Scholar
• HackerMRGeraghtySManco-JohnsonMBarriers to compliance with prophylaxis therapy in haemophiliaHaemophilia20017439239611442644
   PubMed Web of Science ®Google Scholar
• GeorgeLACamireRMProfile of efraloctocog alfa and its potential in the treatment of hemophilia AJ Blood Med2015613114125977610
   PubMedGoogle Scholar
• ThornburgCDPhysicians’ perceptions of adherence to prophylactic clotting factor infusionsHaemophilia2008141252918028395
   PubMed Web of Science ®Google Scholar
• ThornburgCDCarpenterSZappaSMunnJLeissingerCCurrent prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United StatesHaemophilia201218456857422335526
   PubMed Web of Science ®Google Scholar
• KontermannREStrategies for extended serum half-life of protein therapeuticsCurr Opin Biotechnol201122686887621862310
   PubMed Web of Science ®Google Scholar
• SrivastavaABrewerAKMauser-BunschotenEPGuidelines for the management of hemophiliaHaemophilia2013191e1e4722776238
   PubMed Web of Science ®Google Scholar
• BerntorpEShapiroADModern haemophilia careLancet201237998241447145622456059
   PubMed Web of Science ®Google Scholar
• CollinsPWBlanchetteVSFischerKBreak-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia AJ Thromb Haemost20097341342019143924
   PubMed Web of Science ®Google Scholar
• GringeriALundinBvon MackensenSMantovaniLMannucciPMA randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)J Thromb Haemost20119470071021255253
   PubMed Web of Science ®Google Scholar
• Manco-JohnsonMJKemptonCLRedingMTRandomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)J Thromb Haemost20131161119112723528101
   PubMed Web of Science ®Google Scholar
• CollinsPFaradjiAMorfiniMEnriquezMMSchwartzLEfficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover studyJ Thromb Haemost201081838919817995
   PubMed Web of Science ®Google Scholar
• van den BergHMFischerKMauser-BunschotenEPLong-term outcome of individualized prophylactic treatment of children with severe haemophiliaBr J Haematol2001112356156511260054
   PubMed Web of Science ®Google Scholar
• NilssonIMBerntorpELofqvistTPetterssonHTwenty-five years’ experience of prophylactic treatment in severe haemophilia A and BJ Intern Med1992232125321640190
   PubMed Web of Science ®Google Scholar
• FischerKCarlssonKPetriniPIntermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970sBlood201312271129113623777770
   PubMed Web of Science ®Google Scholar
• LjungRProphylactic therapy in haemophiliaBlood Rev200923626727419775786
   PubMed Web of Science ®Google Scholar
• van CreveldSProphylaxis in haemophiliaLancet1971176964504100418
   PubMed Web of Science ®Google Scholar
• AledortLMProphylaxis: the next haemophilia treatmentJ Intern Med19922321121640188
   PubMed Web of Science ®Google Scholar
• Manco-JohnsonMJAbshireTShapiroAProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophiliaN Engl J Med2007357653554417687129
   PubMed Web of Science ®Google Scholar
• ValentinoLAConsiderations in individualizing prophylaxis in patients with haemophilia AHaemophilia201420560761524712891
   PubMed Web of Science ®Google Scholar
• Den UijlIEMFischerKVan Der BomJGGrobbeeDERosendaalFRPlugIClinical outcome of moderate haemophilia compared with severe and mild haemophiliaHaemophilia2009151839018713246
   PubMed Web of Science ®Google Scholar
• DumontJALiuTLowSCProlonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogsBlood2012119133024303022246033
   PubMed Web of Science ®Google Scholar
• RoopenianDCAkileshSFcRn: the neonatal Fc receptor comes of ageNat Rev Immunol20077971572517703228
   PubMed Web of Science ®Google Scholar
• HarrisJMChessRBEffect of pegylation on pharmaceuticalsNat Rev Drug Discov20032321422112612647
   PubMed Web of Science ®Google Scholar
• PasutGVeroneseFMState of the art in PEGylation: the great versatility achieved after forty years of researchJ Control Release2012161246147222094104
   PubMed Web of Science ®Google Scholar
• YatuvRRobinsonMDayan-TarshishIBaruMThe use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophiliaInt J Nanomedicine2010558159120856833
   PubMed Web of Science ®Google Scholar
• SuzukiTIshii-WatabeATadaMImportance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcRJ Immunol201018441968197620083659
   PubMed Web of Science ®Google Scholar
• PetersRTTobyGLuQBiochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion proteinJ Thromb Haemost201311113214123205847
   PubMed Web of Science ®Google Scholar
• PowellJSJosephsonNCQuonDSafety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patientsBlood2012119133031303722223821
   PubMed Web of Science ®Google Scholar
• MahlanguJPowellJSRagniMVPhase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia ABlood2014123331732524227821
   PubMed Web of Science ®Google Scholar
• YoungGMahlanguJKulkarniRRecombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia AJ Thromb Haemost201513696797725912075
   PubMed Web of Science ®Google Scholar
• EMEA. European Medicines AgencyGuideline on the Clinical Investigation of Recombinant and Human Plasma-derived Factor VIII ProductsLondon, UKEMEA2011
   Google Scholar
• FDAGuidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic ProteinsSilver Spring, MDFDA2009
   Google Scholar
• NestorovINeelakantanSLuddenTMLiSJiangHRoggeMPopulation pharmacokinetics of recombinant factor VIII Fc fusion proteinClin Pharmacol Drug Dev20154316317427140796
   PubMed Web of Science ®Google Scholar
• TarantinoMDCollinsPWHayCRClinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia AHaemophilia200410542843715357767
   PubMed Web of Science ®Google Scholar
• ChalmersEYGMahlanguJRechtMTreatment of bleeding with recombinant factor VIII FC fusion protein in previously-treated pediatric subjects with hemophilia A in the phase 3 kids a-long studyPaper presented at: XXV Congress of the International Society on Thrombosis and HaemostasisJune 20–25, 2015Toronto, Canada
   Google Scholar
• FDAantihemophilic factor [recombinant Fc fusion protein] – FDA Clinical Pharmacology BLA Review2013
   Google Scholar
• NolanBMahlanguJPerryDLong-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia AHaemophilia2016221728026218032
   PubMed Web of Science ®Google Scholar
• WightJPaisleySThe epidemiology of inhibitors in haemophilia A: a systematic reviewHaemophilia20039441843512828678
   PubMed Web of Science ®Google Scholar
• KitchenSGrayEMertensKMonitoring of modified factor VIII and IX productsHaemophilia201420Suppl 4364224762273
   PubMed Web of Science ®Google Scholar
• LusherJMHillman-WisemanCHurstDIn vivo recovery with products of very high purity–assay discrepanciesHaemophilia1998446416459873807
   PubMed Web of Science ®Google Scholar
• ViuffDBarrowcliffeTSaugstrupTEzbanMLillicrapDInternational comparative field study of N8 evaluating factor VIII assay performanceHaemophilia201117469570221426445
   PubMed Web of Science ®Google Scholar
• IngerslevJJankowskiMAWestonSBCharlesLACollaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assaysJ Thromb Haemost20042462362815102018
   PubMed Web of Science ®Google Scholar
• BarrowcliffeTWRautSSandsDHubbardARCoagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendationsSemin Thromb Hemost200228324725612098084
   PubMed Web of Science ®Google Scholar
• SommerJMMooreNMcGuffie-ValentineBComparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratoriesHaemophilia201420229430024261554
   PubMed Web of Science ®Google Scholar